|Day Low/High||4.98 / 5.18|
|52 Wk Low/High||3.42 / 6.31|
I'm looking forward to hearing from Progenics Pharmaceuticals and Builders FirstSource.
Here are updates on small biotech/biopharma names I have profiled before.
Let's look at a couple of companies we have covered on these pages before.
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
It's weeks like this that I'm glad I have some 'dry powder' to deploy.
Both biotech stocks are at or near 52-week lows, but don't deserve to be.
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
I expect deal volume to have a substantial uptick before the end of 2018 rolls around.
Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.
Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.
These names are moving up or down in a big way ahead of releasing drug-trial results.
American Society of Clinical Oncology will see presentations from dozens of companies.
After a strong week for the biotech sector, these names have potential catalysts to move shares.
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
Waiting for the market to open on this last day of the trading week. Looks like a slightly up opening based on futures right now. I think there is decent chance equities rally a bit here today and claw back some of yesterday's deep losses. Chinese '...
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
A roundup of biotech names with actions pending at the FDA in coming weeks.
I've added to my positions in these names on yesterday's intraday silliness.
Sector M&A activity is likely to pick up next year benefiting the space.
We are coming my favorite part of earnings season -- when these small-caps report.
The housing market will continue to improve over the next few years due to pent up demand.